Merck and Novo Nordisk Join TransCelerate

January 28, 2015
Applied Clinical Trials Editorial Staff

Applied Clinical Trials

TransCelerate BioPharma Inc. today announced two new members, Merck & Co. Inc., and Novo Nordisk, to the biopharmaceutical non-profit organization.

TransCelerate BioPharma announced two new members, Merck & Co. Inc., and Novo Nordisk, to the biopharmaceutical non-profit organization, bringing the total number of members to 23. In addition, TransCelerate has appointed Briggs Morrison, MD, Executive Vice President, Global Medicines Development at AstraZeneca, to the position of Chair of the Board of Directors.   Read the full release here.